Press Releases

Leadership team additions
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]


January 25, 2022

Bridge Biotherapeutics Enters AI-based Research Collaboration with Atomwise to Expand Pellino Inhibitor Pipeline

The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications, including inflammation SAN FRANCISCO & SEONGNAM, South Korea–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics (KOSDAQ: 288330), a clinical stage biotech company, announced today a research collaboration to launch […]

Atomwise and Bridge Biotherapeutics Sign $1B Deal to Unlock Blockbuster Potential in Inflammation

The collaboration will discover and develop up to 13 small molecule programs, initially targeting Pellino proteins to treat multiple indications SAN FRANCISCO–(BUSINESS WIRE)–Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, and Bridge Biotherapeutics, a clinical stage biotech company, announced today a research collaboration to launch up to 13 small molecule programs […]

BioMotiv and Atomwise Sign AI Partnership to Transform Therapeutic Development

Strategic collaboration to integrate AI technology, drug development expertise and ecosystem of partners for the commercialization of promising early-stage research CLEVELAND & SAN FRANCISCO–(BUSINESS WIRE)–BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, today announced a strategic collaboration to co-develop therapies. The organizations will form co-owned, joint […]

Bayer Exercises Right to Enter Into Follow-On Research and Collaboration Option Agreement With Atomwise

Companies to continue crop protection development programs January 07, 2020 08:30 AM Eastern Standard Time MONHEIM, Germany & SAN FRANCISCO–(BUSINESS WIRE)–Bayer and Atomwise, the leader in artificial intelligence (AI) for drug discovery, today announced the companies will continue the development of two crop protection programs. Farmers across the world are facing an increase in weed, insect and […]


January 7, 2020
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery

Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.

Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas

Hansoh Pharmaceutical Group Company Limited, a leading biopharmaceutical company in China, and Atomwise, Inc., the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.


September 11, 2019